The acute effect of metabolic cofactor supplementation: a potential therapeutic strategy against non-alcoholic fatty liver disease by Zhang, C. et al.
The acute effect of metabolic cofactor supplementation: a
potential therapeutic strategy against non-alcoholic fatty liver
disease
Downloaded from: https://research.chalmers.se, 2021-08-31 11:51 UTC
Citation for the original published paper (version of record):
Zhang, C., Björnson, E., Arif, M. et al (2020)
The acute effect of metabolic cofactor supplementation: a potential therapeutic strategy
against non-alcoholic fatty liver disease
Molecular Systems Biology, 16(4)
http://dx.doi.org/10.15252/msb.209495
N.B. When citing this work, cite the original published paper.
research.chalmers.se offers the possibility of retrieving research publications produced at Chalmers University of Technology.
It covers all kind of research output: articles, dissertations, conference papers, reports etc. since 2004.
research.chalmers.se is administrated and maintained by Chalmers Library
(article starts on next page)
Article
The acute effect of metabolic cofactor
supplementation: a potential therapeutic strategy
against non-alcoholic fatty liver disease
Cheng Zhang1,2,† , Elias Bjornson3,4,†, Muhammad Arif1,†, Abdellah Tebani1 , Alen Lovric1,‡,§,
Rui Benfeitas1,¶ , Mehmet Ozcan1 , Kajetan Juszczak1, Woonghee Kim1, Jung Tae Kim1,
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Abstract
The prevalence of non-alcoholic fatty liver disease (NAFLD) contin-
ues to increase dramatically, and there is no approved medication
for its treatment. Recently, we predicted the underlying molecular
mechanisms involved in the progression of NAFLD using network
analysis and identified metabolic cofactors that might be benefi-
cial as supplements to decrease human liver fat. Here, we first
assessed the tolerability of the combined metabolic cofactors
including L-serine, N-acetyl-L-cysteine (NAC), nicotinamide riboside
(NR), and L-carnitine by performing a 7-day rat toxicology study.
Second, we performed a human calibration study by supplement-
ing combined metabolic cofactors and a control study to study the
kinetics of these metabolites in the plasma of healthy subjects
with and without supplementation. We measured clinical parame-
ters and observed no immediate side effects. Next, we generated
plasma metabolomics and inflammatory protein markers data to
reveal the acute changes associated with the supplementation of
the metabolic cofactors. We also integrated metabolomics data
using personalized genome-scale metabolic modeling and
observed that such supplementation significantly affects the
global human lipid, amino acid, and antioxidant metabolism.
Finally, we predicted blood concentrations of these compounds
during daily long-term supplementation by generating an ordinary
differential equation model and liver concentrations of serine by
generating a pharmacokinetic model and finally adjusted the doses
of individual metabolic cofactors for future human clinical trials.
Keywords L-serine, N-acetyl-L-cysteine (NAC), nicotinamide riboside (NR), and
L-carnitine; NAFLD; systems medicine
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Introduction
Hepatic steatosis (HS) is defined as the accumulation of large
vacuoles of triglycerides in the liver (> 5.5% tissue weight) due to an
imbalance between lipid deposition and lipid removal from the liver
(Solinas et al, 2015; Francque et al, 2016; Samuel & Shulman, 2018).
Non-alcoholic fatty liver disease (NAFLD) encompasses a broad spec-
trum of pathological conditions, ranging from simple HS to various
degrees of liver inflammation such as non-alcoholic steatohepatitis
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(NASH), which can progress to severe liver diseases, including
cirrhosis and hepatocellular carcinoma (HCC). The prevalence of
NAFLD continues to increase dramatically, and it has reached 25% at
the population level (Estes et al, 2018) with the progressive
epidemics of obesity and type 2 diabetes mellitus (T2DM). There are
at present no approved effective medications for treating NASH.
In order to resolve the pathophysiology of NAFLD and to reveal
the underlying molecular mechanisms involved in the progression
towards NASH, a systems biology approach which enables integra-
tion and analysis of multi-layer omics data through the use of
biological networks has been employed (Mardinoglu & Nielsen,
2015; Mardinoglu & Uhlen, 2016; Bosley et al, 2017; Mardinoglu
et al, 2018a,b). Earlier, we generated a functional liver-specific
genome-scale metabolic model (GEM) (Mardinoglu et al, 2014) and
an integrated network (IN) (Lee et al, 2016) by merging GEMs with
regulatory and protein–protein interaction networks. This integra-
tive approach allows not only to reveal the key pathways, metabo-
lites, and genes involved in the progression of liver diseases, but
also to make solid predictions that can be experimentally tested due
to the known regulatory effect of other proteins on metabolism.
Recently, we have combined clinical studies with stable isotopes,
in-depth multi-omics profiling, and liver-specific networks to clarify
the underlying mechanisms of NAFLD and develop strategies for
prevention and treatment (Mardinoglu et al, 2017). Our integrative
multi-tissue analysis has indicated that NAFLD patients have
reduced de novo synthesis of glutathione (GSH) due to limited avail-
ability of serine and glycine, resulting in altered GSH and NAD+
metabolism, which is a prevailing feature of NAFLD. To test the
model-based predictions, we assessed the effect of short-term serine
supplementation in NAFLD patients by providing an oral dose of
~ 20 g of L-serine (200 mg/kg) per day for 14 days showing that
liver enzymes (ASAT, ALAT, ALP) and plasma triglycerides, as well
as the amount of fat in liver were significantly decreased after
supplementation of serine (Mardinoglu et al, 2017). Our model also
indicated that supplementation of L-carnitine as well as precursors
of GSH and NAD+ including L-serine, N-acetyl-L-cysteine (NAC),
and nicotinamide riboside (NR) would decrease liver fat accumula-
tion by promoting the fat uptake and its oxidation in the mitochon-
dria as well as generation of GSH required in the liver (Mardinoglu
et al, 2017). These predictions were further tested in a mouse study
and supplementation with such a formulation decreased the amount
of liver fat (Mardinoglu et al, 2017).
Here, we first performed a 7-day rat toxicology to study tolerabil-
ity of the combined metabolic cofactors and measured clinical
parameters to identify potential side effects. Next, we performed a
5-day human calibration study by supplementing naturally occur-
ring metabolic cofactors including 20 g L-serine, 3 g L-carnitine, 5 g
NAC, and 1 g NR and a control study to reveal the acute global
effect of the supplementation of combined metabolic cofactors by
eliminating the effect of the fasting. We generated plasma metabolo-
mics and inflammatory protein markers data to reveal the changes
associated with the supplementation of these metabolic cofactors
and measured the kinetics of the metabolites and proteins in the
plasma of the healthy subjects. Next, we predicted altered path-
ways, reactions, and metabolites in liver due to the supplementation
of the metabolic cofactors using metabolomics data and personal-
ized genome-scale metabolic modeling. Moreover, we developed an
ordinary differential equation (ODE) model to predict blood
concentrations of each metabolic cofactor during daily long-term
supplementation and adjusted their doses. Finally, we analyzed
literature data and the data generated in the supplementation study
using pharmacokinetic (PK) modeling and statistical analysis.
Results
Seven-day oral (gavage) tolerability study in the rat
We performed a 7-day oral (gavage) toxicology study in the Wistar
Hannover rats (without blinding) and assessed the tolerability of the
combined metabolic cofactors including L-serine, NAC, NR, and L-
carnitine tartrate (salt form of L-carnitine) at intended human clini-
cal doses (Formulation I) and 10-fold (Formulation II) and 30-fold
(Formulation III) dose levels. We assessed body weight, hematol-
ogy, plasma chemistry, and gross pathology during the study.
Three groups of rats, each consisting of three females to acquire
minimal required statistical power (without randomization), were
given combined metabolic cofactors orally, once a day for 7 days.
The dose levels administered are presented in Table EV1. From
available data on the individual components, Formulation I was not
expected to produce any adverse effects. In Formulations II and III,
the levels of some of the components were approaching known
tolerability levels; hence, adverse effects could be expected.
Several observations (e.g., plowing with the nose in the bedding
material and excessive chewing) were made in all groups in connec-
tion with, or shortly after dosing, and are not considered of toxico-
logical significance. Most severe observations, such as ataxia,
cyanosis, irregular and/or respiration and decreased motor activity,
were observed in Group 3 at Days 1 and 2. This led to a lowering of
the dose (33%) in this group on Day 3. The new dose level was well
tolerated for the remainder of the study. In all groups, some milder
signs of discomfort (eyes half-shut and pilo-erection) were observed
at Day 1, but were not present from Day 2 in Groups 1 and 2. This
may only indicate a reaction to a new, unknown treatment, but may
also indicate a tolerability buildup after repeated exposure.
We observed that none of the doses administered in this study
caused any significant changes (Appendix Table S1) in hematological
(Appendix Table S2) and plasma chemistry parameters (Appendix
Table S3). We also did not detect any significant changes by the
pathology analysis or during the macroscopic analysis at necropsy.
Human calibration study with natural metabolic cofactors
We performed a 5-day calibration study by recruiting nine healthy
male subjects without any medication (age 26–36 years, BMI 19.4–
34.5 kg/m2) to identify the acute global effect of metabolic cofactors
supplementation (Fig 1A, Table EV2). The subjects stayed in the
same hotel, had the same breakfast, and did not eat/drink anything
until the end of the study in each day. We supplemented each of the
four metabolic cofactors NR, L-carnitine, NAC, and L-serine to all
subjects at separate days as well as the combined metabolic cofac-
tors (i.e., a cocktail of the substances) at another day. Based on liter-
ature information, we supplemented 20 g L-serine, 3 g L-carnitine,
5 g NAC, and 1 g NR per day (Hurd et al, 1996; Hathcock & Shao,
2006; Garofalo et al, 2011). The study started at 8:00 every day and
blood samples were collected before and 4 h after the
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Breakfast T0 T1 T2 T3 T4 T5 T6 T7
Supp.
(9 subjects)
7:00 8:00 9:00 10:00 11:00 12:00 13:00 14:00 15:30
Control
(10 subjects)
7:00 8:00 9:00 10:00 11:00 - 13:00 - 15:30
20 g serine 
3 g L-carnitine 
5 g NAC 
1 g NR
Calibraon study





12.35 g serine 
2.55 g L-carnitine 
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supplementation of individual metabolic cofactors. At the day we
supplemented the combined metabolic cofactors, eight blood
samples were collected during the day (Fig 1A). We measured the
plasma level of glucose, insulin, free fatty acids, triglycerides, total
cholesterol, HDL, LDL, and known liver markers including gamma
GT, bilirubin, ASAT, ALAT, ALP before and after the study, and
observed no significant differences (Table EV2). Subjects involved
in the study did not report any side effect. Our analysis below
focused on the day, where we supplemented the combined meta-
bolic cofactors.
After 21 months, we asked the subjects involved in the study to
run a follow-up control study and five of the subjects responded
positively. We recruited another five healthy subjects and run a 1-
day control study with 10 male subjects without any medication
(age 26–36 years, BMI 19.8–35.8 kg/m2) following the same study
design in the metabolic cofactor supplementation study. Subjects
stayed in the same hotel, had the same breakfast, and did not eat/
drink anything until the end of the study. The study started at 8:00,
and six blood samples were collected during the day after drinking a
glass of water (Fig 1A).
Plasma metabolites associated with the supplementation of
metabolic cofactors
We first quantified the plasma levels of L-serine, L-carnitine, and
NAC using targeted metabolomics on the day we supplemented the
combined metabolic cofactors and observed that supplementation of
each metabolite increased the plasma levels proportionally
(Appendix Fig S1 and Table EV3). We also generated untargeted
metabolomics data using the plasma samples (Table EV4) and con-
firmed that plasma level of L-serine, L-carnitine, cysteine, and nicoti-
namide is increased after supplementation (Fig 1B). We observed a
high degree of correlation between the serine (Pearson, r = 0.99)
and L-carnitine (Pearson, r = 0.95) levels detected using targeted
and untargeted metabolomics analysis, as expected.
We have earlier shown that plasma levels of kynurenine, kynure-
nate, pyruvate, and ornithine are significantly positively associated
with increased liver fat (Mardinoglu et al, 2017). We first investi-
gated whether supplementation of the combined metabolic cofactors
affected the plasma level of these substances (Table EV5). We found
that plasma levels of kynurenine (Fig 2A), kynurenate (Fig 2B),
pyruvate (Fig 2C), and ornithine (Fig 2D) were significantly
decreased after the supplementation compared to baseline. In addi-
tion to the decrease in the plasma level of lipid structures
(Appendix Figs S2 and S3), we also found that plasma levels of
branch chain amino acids (BCAAs) including leucine (Fig 2E),
isoleucine (Fig 2F), and valine (Fig 2G) which are significantly asso-
ciated with insulin resistance and future incidence of T2D were
significantly decreased after supplementation compared to baseline.
In order to investigate if the decrease in the plasma levels of these
metabolites was associated with the supplementation of the meta-
bolic cofactors, we performed a correlation analysis between these
metabolites and supplemented metabolic cofactors (Table EV6,
Appendix Figs S4 and S5). We found that the decreased plasma level
of kynurenine is significantly negatively correlated with carnitine
and NR; kynurenate is significantly negatively correlated with
serine; pyruvate is significantly negatively correlated with NR and
cysteine; and ornithine is significantly negatively correlated with
serine (Fig 2H). We also observed that the decreased plasma level
of BCAAs was significantly negatively correlated with plasma level
of serine.
In order to eliminate the fasting effect on the kinetics of the
plasma metabolites, we also generated untargeted metabolomics
data using the plasma samples from the control study and detected
the plasma level of 630 metabolites (Table EV7) of which 96
metabolites were detected in both studies (Table EV8). We observed
that none of the significant correlations between the metabolites
associated with increased liver fat and supplemented metabolic
cofactors were identified in the control study.
Next, we studied the kinetics of the plasma metabolites by
comparing to the baseline in the supplementation and control study
(Fig 3A). We observed that the plasma levels of L-serine, L-carnitine,
and cysteine were significantly different and showed different
dynamics, as expected. For instance, we found that both the L-serine
and L-carnitine levels kept almost constant in the control study which
are opposite to their rapid increase exhibited in the supplementation
study (Fig 1C). Interestingly, we found that the plasma cysteine level
between the two studies has been shifted during the experiment,
where it is significantly higher in the first 2 h but much lower in the
last 2 h in the supplementation study (Fig 1C). This indicated that
the supplementation not only boosted the cysteine level in the first
half of the experiment, but also increased its consumption during the
whole study. We also identified the metabolites showing the same
and opposite trends in two studies. In addition to the plasma level of
supplemented metabolic cofactors, directly associated metabolites
to these cofactors including betaine, choline, glycine, cystine, carni-
tine derivatives; as well as other metabolites including citrulline,
trimethylamine N-oxide (TMO), homoarginine, cortisone, and
dimethylarginine showed opposite trend in two different studies.
Finally, to systematically evaluate the differences between two
the studies and to eliminate the fasting effect, we compared the
plasma levels of these metabolites between the subjects for each
time point and identified 18 metabolites that were significantly
(ANOVA test, adjusted P < 0.05) altered in at least three time points
(Fig 3B). We observed the plasma level of citrulline (Fig 3C), TMO
(Fig 3D), and dimethylarginine (Fig 3E) showed consistently signifi-
cant differences. Citrulline is a key metabolite in the urea cycle, and
its supplementation has been suggested to prevent the development
of NAFLD (Sellmann et al, 2017). TMO is also significantly associ-
ated with NAFLD, and it is known as a potential plasma biomarker
◀ Figure 1. Calibration study with the supplementation of metabolic cofactors.A Summary of the metabolic cofactor supplementation and control study as well as the dosage of the metabolic cofactors before (left regimen) and after (right
regimen) dosage adjustment based on this study.
B Changes in plasma level of each cocktail substances in both supplementation and control studies (NR is detected in control study) compared to time baseline based
on untargeted metabolomics measurement. The gray shaded area represents the 95% confidence level interval. For boxplots limits, the middle line represents the
median. The upper and lower box limits represent the 25% quantiles. The upper and lower error bars correspond to 75% quantiles. The P-values are derived from one-
way ANOVA (FDR < 0.05).
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Figure 2. The changes in the plasma level of NAFLD associated metabolites due to the supplementation.
A–G Changes in plasma level of key metabolites compared to time baseline (solid line) based on untargeted metabolomics measurement in metabolic cofactor
supplementation study. The upper and lower box limits represent the 25% quantiles. The upper and lower error bars correspond to 75% quantiles. *Denotes
significance (one-way ANOVA; FDR < 0.05).
H Spearman correlation (visualized by Circlize) between plasma levels of supplemented metabolic cofactors and key metabolites associated with high liver fat and
insulin resistance. *Denotes significance (FDR < 0.05).
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of NAFLD (Chen et al, 2016). The circulating dimethylarginine level
is also related to NAFLD in previous studies (Kasumov et al, 2011).
Taken together, global plasma metabolomics analysis based on
supplementation and control study suggested that the supplementa-
tion of metabolic cofactors significantly improves the altered meta-
bolism in NAFLD.
Inflammatory protein markers associated with the
supplementation of metabolic cofactors
We measured the plasma levels of 67 inflammation-related protein
markers using proximity extension assay (PEA) proteomics-based
inflammation panel (detected in more than 80% of the samples) in
the supplementation (Table EV9) and control study (Table EV10).
We observed significant reductions in plasma level of the inflamma-
tory markers including fibroblast growth factor 21 (FGF21), FGF 19,
osteoprotegerin (OPG), TNF receptor superfamily member 9
(TNFRSF9), C-C motif chemokine 23 (CCL23), CCL25, matrix metal-
loproteinase 1 (MMP1), MMP10, Fms-related tyrosine kinase 3 ligand
(FLT3LG), TRANCE, interleukin 17C (IL-17C), IL-10, glial cell-derived
neurotrophic factor (GDNF), and other inflammatory protein markers
in the supplementation study compared to its baseline (Fig 4A).
We next measured the plasma levels of the protein markers in
the control study. We found the plasma level of FGF19, MMP1,
MMP10, FLT3L, TRANCE, CCL25, IL-10 is also significantly
decreased compared to the baseline in the control study (Fig 4A),
which suggested that their decrease in the supplementation study
may be due to the fasting of the subjects.
To systematically evaluate the differences between two studies, we
also compared the plasma levels of these inflammatory markers
between the subjects for each time point and presented the markers
that were significantly (ANOVA test, adjusted P < 0.05; Table EV11)
altered in at least two time points (Fig 4B). We found that plasma level
of four different markers including FGF21 (Fig 4C), OPG (Fig 4D),
TNFRSF9 (Fig 4E), and CCL23 (Fig 4F) was significantly decreased
with the supplementation after removing the effect of fasting.
Previous studies have shown that plasma level of FGF21 is
elevated in NAFLD patients, and it is positively correlated with high
liver fat in both mice and human (Dushay et al, 2010; Li et al, 2010,
2013; Rusli et al, 2016). The plasma level of FGF21 has also been
suggested as a potential diagnostic marker of NAFLD. Consistent
with these findings, we showed that supplementation of the meta-
bolic cofactors significantly decreased the plasma level of FGF21
compared to baseline after eliminating the fasting effect. The rapid
reduction in the plasma level of FGF21 agrees with our recent study
where the plasma concentrations of FGF21 are decreased in parallel
to the decrease in liver fat with a carbohydrate-restricted diet
(Mardinoglu et al, 2018c).
There is also study reported that there is a link between
TNFRSF9/CD137 and NAFLD in mice, showing that deficiency of
TNFRSF9/CD137 prevents the mice from the development of
NAFLD (Kim et al, 2011b). Hepatic cells are known to be able to
produce OPG, and the plasma level of OPG has been shown to be
positively correlated with liver fat content in dysmetabolic adults
(Monseu et al, 2016). The plasma level of CCL23 has also been
associated with plasma oxidative low-density lipoprotein (Kim et al,
2011a), which could affect the redox balance in hepatic cells, and
the latter has been linked to hepatic steatosis in recent studies
(Walenbergh et al, 2013). Finally, we observed that the plasma level
of MMP1 showed significant differences due to the supplementation.
The decreased plasma level of MMP1 has been associated with
NAFLD in previous studies (Mahmoud et al, 2012; Schuppan et al,
2018). Hence, our analysis of plasma inflammation protein markers
in the supplementation and control studies suggested that the
supplementation may significantly affect the inflammation markers
that are associated with NAFLD.
Global effect in liver using liver GEMs
To investigate the potential global metabolic effect of the combined
metabolic cofactors supplementation in liver, we integrated the
untargeted metabolomics data and a comprehensive liver GEM,
which is the representative of liver metabolism (Mardinoglu et al,
2014). Initial constraints in liver GEM were retrieved from
measured liver flux data and literature reports (Felig et al, 1974;
Hyotylainen et al, 2016; Mardinoglu et al, 2017). We set a manda-
tory ATP hydrolysis rate in the model to account for the resting
energy expenditure of the organ that is calculated based on
◀ Figure 3. The effect of supplementation on plasma metabolites.A A summary of significantly different plasma metabolites compared to time baseline in metabolic cofactor supplementation and control studies based on
untargeted metabolomics measurements. Red and blue colors denote the increased and decreased plasma levels compared to baseline, respectively. *Denotes
significance (one-way ANOVA; FDR < 0.05).
B Metabolites significantly different between supplementation and control studies. Red and blue colors denote the increased and decreased plasma level in
supplementation study compared to control study, respectively. *Denotes significance (one-way ANOVA; FDR < 0.05).
C–E Changes in plasma level of key metabolites compared to time baseline based on untargeted metabolomics measurement in supplementation and control studies.
The gray shaded area represents the 95% confidence level interval.
▸Figure 4. The effect of supplementation on plasma inflammatory markers.A A summary of significantly different plasma inflammatory protein markers compared to time baseline in metabolic cofactor supplementation and control studies.
Red and blue colors denote the increased and decreased plasma levels compared to baseline, respectively. *Denotes significance (one-way ANOVA; FDR < 0.05).
B Proteins significantly different between supplementation and control studies. Red and blue colors denote the increased and decreased plasma level in
supplementation study compared to control study, respectively. *Denotes significance (one-way ANOVA; FDR < 0.05).
C–F Changes in the plasma level of key proteins compared to time baseline based on untargeted metabolomics measurement in supplementation and control studies.
The gray shaded area represents the 95% confidence level interval. For boxplots limits, the middle line represents the median. The upper and lower box limits
represent the 25% quantiles. The upper and lower error bars correspond to 75% quantiles. The P-values are derived from one-way ANOVA (FDR < 0.05).
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previous experimental studies (McClave & Snider, 2001). We also
incorporated the personalized changes in the plasma metabolite
levels between the supplementation and control studies as addi-
tional constraints to the model for systematic interpretation of the
metabolomics data. For instance, citrulline is increased in the
plasma of the first subject with metabolic cofactor supplementa-
tion, and it is incorporated into the personalized model as either
its consumption/secretion is decreased/increased in response to
the supplementation. Moreover, we used oxidation of fat as an
objective function since such supplementation can boost oxidation
of fat in liver and eventually decrease the amount of fat in the
liver. Finally, we predicted intracellular fluxes for five subjects
who participated in both supplementation and control studies in a
personalized manner using an adapted version of a previous
method (Mardinoglu et al, 2015; Materials and Methods). The liver
GEM used in this study together with all constraints and objective
function is provided in Table EV12.
We performed the simulations for each individual involved in
both studies, presented the model simulation results in
Table EV13, and summarized the results in Fig 5A. First, we
compared the fluxes of total fatty acid oxidation (set as an objec-
tive function) and found that these fluxes increased after
combined metabolic cofactors supplementation compared to
control study (Fig 5B). This prediction is in line with our assump-
tions and indicated that the supplementation of metabolic cofac-
tors could promote oxidation of fat in liver. Second, we
investigated the fluxes in glutathione synthesis and observed that
flux carried by the reaction is increased due to the
supplementation of serine and NAC (Fig 5C–E). Moreover, we
compared the global intracellular fluxes predicted by the model
and observed increased uptake and oxidation of BCAAs
(Fig 5F–K) and increased flux turnovers for both NAD+ (Fig 5L)
and L-carnitine (Fig 5M), indicating activation of mitochondria
after the supplementation of metabolic cofactors. We also detected
slight decrease in the fluxes carried by the reactions involved in
glycolysis, indicating the inhibition of glucose metabolism (Fig 5N
and O). Finally, we observed an increased flux of high-density
lipoprotein secretion with supplementation of metabolic cofactors
(Fig 5P and Q), which suggested another potential benefit effect of
the supplementation in the liver fatty acids metabolism.
Adjustment of the dose based on calibration study
Using the targeted metabolomics data obtained from the plasma of
nine subjects, we developed a three-compartment ODE pharmacoki-
netic model to represent metabolic cofactors distribution within the
body. The model structure was inferred from a mechanistic view of
holdup in the stomach and absorption from the small intestine to
the blood, with central clearance. The model was simultaneously fit-
ted to the experimentally measured plasma concentrations for all
subjects. Similar compartmental models for each metabolic cofactor
were developed and fitted to measured plasma concentrations. Data
used were from the nine subjects over the course of up to 24 h after
supplementation. The models were fitted using a pooled-data
approach, and bioavailability of each metabolic cofactor was set











































































Figure 5. The effect of supplementation on liver metabolism based on metabolic modeling.
A A summary of altered metabolic fluxes in liver by integrating metabolomics data accounting individual variations. Solid arrows indicate one or more metabolic
reactions. Plasma metabolites increased due to metabolic cofactor supplementation are highlighted in rounded rectangle frames. The red/blue color of arrows and
metabolite names indicate increased/decreased flux/pool with metabolic cofactor supplementation compared to control study.
B–Q Changes in fluxes of key metabolic reactions highlighted in (A) compared to baseline fluxes (dashed line) based on personalized modeling, where “SX” indicating
flux obtained by the modeling of subject number “X” as shown in Table EV13.
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Interpolations of the plasma concentrations of each metabolic
cofactor were constructed for every subject. The mean of the inter-
polations was used as the target concentration curve and the model
was subsequently fitted to this curve. Once the model was fitted to
each metabolic cofactor, the model was used to predict the resulting
plasma concentration when subject to a twice-daily supplementa-
tion regimen. The individual dosages of the metabolic cofactors
were adjusted to achieve a desired 100% increase in average (long
term) plasma concentration without superseding safe doses for
human consumption.
Interpolations of serine for each subject are displayed in Fig 6A
and model fit to the mean plasma serine level is displayed in Fig 6B.
The model predicts that a twice-daily dose of 12.75 g serine may
produce a desired long-term increase in mean plasma serine concen-
tration of 100% (Fig 6C). Doses up to 400 mg/kg/day (around 25–
30 g/day) have been studied in humans and shown to be safe
(Garofalo et al, 2011).
Interpolations of L-carnitine for each subject are displayed in
Fig 6D, and model fit to the mean plasma L-carnitine level is
displayed in Fig 6E. The model predicts that a twice-daily dose of
8.3 g L-carnitine will produce a desired long-term increase in mean
plasma L-carnitine concentration of 100% (Appendix Fig S6).
However, since long-term supplementation studies for the safety of




Figure 6. Adjustment of the dose based on pharmacokinetic modeling.
A Plasma serine interpolations for each of the nine subjects.
B Model fit to the target concentration curve (mean interpolation of plasma serine over 24 h) with standard deviation indicated in gray.
C Predicted plasma serine during 2 weeks of simulated twice-daily supplementation: 24-h moving average value indicated in red and continuous/momentaneous
indicated in gray.
D Plasma L-carnitine interpolations for each of the nine subjects.
E Model fit to the target concentration curve (mean interpolation of plasma L-carnitine over 24 h) with standard deviation indicated in gray.
F Predicted plasma L-carnitine during 2 weeks of simulated twice-daily supplementation: 24-h moving average value indicated in red and continuous/momentaneous
indicated in gray.
G Plasma NAC interpolations for each of the nine subjects.
H Model fit to the target concentration curve (mean interpolation of plasma serine over 24 h) with standard deviation indicated in gray.
I Predicted plasma NAC during 2 weeks of simulated twice-daily supplementation: 24-h moving average value indicated in red and continuous/momentaneous
indicated in gray.
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Shao, 2006), the dose was reduced to 2.55 g twice daily (Fig 6F).
This resulted in a long-term increase in mean plasma concentration
of 31% (Fig 6F), which was considered a reasonable trade-off
between risk of toxicity and increase in L-carnitine plasma concen-
tration.
Interpolations of NAC for each subject are displayed in Fig 6G,
and model fit to the mean plasma NAC level is displayed in Fig 6H.
The model predicts that a twice-daily dose of 2.47 g NAC will
produce a desired long-term increase in mean plasma NAC concen-
tration of 100% (Fig 6I). A daily dosage of 4–6 g of NAC has been
shown to be safe in humans (Hurd et al, 1996).
Regarding the dose adjustment of the NR, we used existing litera-
ture studies rather than performing additional modeling. Trammell
et al (Trammell et al, 2016) supplemented 1 g/day NR for 7 days to
one subject. Ten initial PBMC NAD+ measurements were performed
during the first 24 h, and one additional plasma NAD+ measure-
ment was performed after 7 days. Moreover, human data for NR
pharmacokinetics in eight subjects with a non-compartmental analy-
sis are available (Airhart et al, 2017). The study was a non-rando-
mized, open-label PK study of eight healthy volunteers, 250 mg NR
was orally administered on Days 1 and 2, and then up titrated to
peak dose of 1,000 mg, twice daily on Days 7 and 8 (Airhart et al,
2017). On the morning of day 9, subjects completed a 24-h PK study
after receiving 1,000 mg NR at t = 0. Whole-blood levels of NR, clin-
ical blood chemistry, and NAD+ levels were analyzed. Oral NR was
well tolerated with no adverse events. Significant increases compar-
ing baseline to mean concentrations at steady state were observed
for both NR (P = 0.03) and NAD+ (P = 0.001); the latter increased
by 100%. Absolute changes from baseline to Day 9 in NR and
NAD+ levels correlated highly (R2 = 0.72, P = 0.008). Considering
the published experimental data, we decided to supplement 1 g of
NR twice daily.
Based on the results of the ODE modeling and literature data, we
concluded that supplementation of 12.35 g serine, 2.55 g of L-carni-
tine, 2.55 g of NAC, and 1 g of NR twice daily can be used for effec-
tive treatment of subjects. Considering that L-carnitine tartrate (salt
form of L-carnitine) contains 67.6% of L-carnitine, 3.75 g L-carnitine
tartrate twice daily can be used for effective treatment of subjects.
The modeling technique used to generate the graphs in Fig 6A–I,
applied the pooled-data approach, where parameters were adjusted
in the model to fit all subject data, simultaneously. The serine data
were also analyzed using a population pharmacokinetic modeling
approach with non-linear mixed-effect techniques. That analysis
applied quantitative systems pharmacology (QSP) techniques, in
which the physiologically meaningful parameters derived from our
clinical data could be checked with available literature data. Human
data for important parameters (such as endogenous serine produc-
tion) were limited. Tsai et al (2008) provided volume and clearance
values, but not separately from oral bioavailability. Wilcox et al
(1985) provided additional data in psychotic and non-psychotic
subjects. These data did allow bounding of model parameters. By
using the limited literature data, we were able to better understand
and quantify the physiology of serine uptake implied by modeling of
our clinical results. The conclusions for dosing derived from both
the pooled PK and QSP population techniques were identical. A
more complete description of the QSP population modeling
approach for serine will be reported elsewhere (preprint: Bosley
et al, 2019).
Discussion
We performed a calibration study by supplementing metabolic
cofactors including L-serine, NAC, NR, and L-carnitine based on our
previous study, where we proposed that the supplementation of
such cofactors may boost uptake and oxidation of fatty acids in
mitochondria and eventually decreased the amount of fat in liver
(Mardinoglu et al, 2017). The rational of the supplementation is that
liver itself has capacity to oxidize fat stored in liver in NAFLD
patients. This has been justified in our recent study, where we
showed that the liver fat content is decreased more than 40% by
providing high fat and protein diet during 2 weeks in NAFLD patient
(Mardinoglu et al, 2018c).
In our study, we performed a 7-day rat study to assess the tolera-
bility of the combined metabolic cofactors including L-serine, NAC,
NR, and L-carnitine and observed that none of the administered
doses caused any detectable hematological, plasma chemistry or
tissue effects. To study the potential immediate toxic effect of the
combined metabolic cofactors in humans, we measured various
clinically relevant biochemical parameters and observed no signifi-
cant effect in a 5-day study.
We also generated untargeted metabolomics data and revealed
the metabolic reprogramming in response to supplementation using
a liver GEM. We found that the oxidation of fatty acids, de novo
synthesis of GSH and catabolism of BCAAs was significantly
increased whereas the consumption of glucose was significantly
decreased after the supplementation of metabolic cofactors. Consid-
ering that these pathways are significantly associated with the
progression of NAFLD, supplementation of metabolic cofactors may
decrease the amount of fat in the liver of NAFLD patients.
Moreover, we obtained a very good agreement between the
metabolic response in liver and the predicted effect of the meta-
bolic cofactor supplementation. This highlights the great advantage
of using natural metabolites as drugs, as the effects of natural
metabolites may be more predictable. Compared to other types of
drugs such as small molecules and proteins, we may have much
more knowledge about the interactions of metabolites in human
body based on GEMs and could predict the potential effect of such
cofactors using tissue/cell-specific GEMs in a systematic way.
Moreover, since the metabolites are already found in our bodies,
we minimize the risk of some common problems in drug discover-
ies such as off-targeting and solubility, and we would expect much
less side effect compared to small molecules. In this context, using
a natural metabolic cofactor supplementation as medication could
represent a promising direction in rational drug development espe-
cially in metabolism-related diseases including NAFLD, T2D, and
cardiovascular diseases. Therefore, our study can be considered as
a pivotal study indicating the power of this new direction in
medicine.
We also applied pharmacokinetic modeling based on the
dynamic metabolomics data. This allowed us to predict the long-
term concentration response when supplementing the metabolites
under a twice-daily supplementation regimen and it allowed deter-
mination of a physiologically feasible dosage. No predictions were
made regarding variability of response between subjects. The
predictions are also limited with regard to the phenotype of the test
group (healthy subjects) and it is therefore possible that different
groups would respond differently. Future supplementation studies
ª 2020 The Authors Molecular Systems Biology 16: e9495 | 2020 11 of 16
Cheng Zhang et al Molecular Systems Biology
particularly related to traditional medicines could however use these
predictions in order to design a supplementation regimen.
During pharmacokinetic modeling, a 100% increase was chosen
as a partly arbitrary desired increase. If this increase however
resulted in a dose larger than what was considered safe, the upper
safe dose was used instead. An equally clinically effective lower
dose than a 100% increase from baseline is not previously known;
thus, we could not use such information when deciding the target
dose. When supplementation starts the plasma concentration will,
in the short-run, rise until a new long-term (approximate) steady
state is reached. Depending on the compound, this new state will be
reached in the order of days, after which the new long-term concen-
tration will be maintained by further supplementation (continuing
weeks to months or more).
The standard error of the estimated parameters k1 and k2 for the
L-carnitine and NAC model is high (> 100% and > 1,000% respec-
tively), meaning these parameters can assume different values and
still fit the experimental data. This uncertainty may have been
reduced if prior physiologic information on k1 and k2 had been
available or if an alternative model would have been constructed.
However, looking across the compounds serine, L-carnitine, and
NAC, the k1 parameter estimation is relatively similar (around three-
fold difference in estimated parameter value) compared to the esti-
mation of k2 across compounds (around 20-fold difference in
estimated parameter value). This points to a similar time dynamic
across compounds in the stomach and small intestine and thus the
difference in blood kinetics mainly being a result of the removal
from the bloodstream rather than the influx into the bloodstream.
This is physiologically plausible; thus, the final parameter estima-
tions are arguably sensible.
In addition to fitting pharmacokinetic models to pooled data, we
also applied population PK modeling to the serine data. The results
from the naı̈ve pooled-data and population approaches with respect to
dose adjustment of serine were identical. This population PK model
also exploited physiological data and known physiology to yield a
QSP model, which matched not only the data from this calibration
study, but also published data. The combination of population PK and
QSP techniques provided more insight into (for example) endogenous
generation of serine. These results will be presented elsewhere
(preprint: Bosley et al, 2019).
Based on integrative analysis, we found that the oxidation of
fatty acids, de novo synthesis of GSH, and catabolism of BCAAs
were significantly increased whereas the consumption of glucose
was significantly decreased after the supplementation of metabolic
cofactors. Taken together, we observed that supplementation of
these metabolic cofactors may provide a therapeutic strategy against
NAFLD progression by promoting the uptake and oxidation of fat in
mitochondria. Hence, we propose testing of metabolic cofactors in a
randomized double-blind placebo-controlled human study to evalu-
ate its long-term efficacy in NAFLD/NASH patients.
Material and Methods
Seven-day oral (gavage) tolerability study in the rat
We performed a rat study to provide a preliminary assessment of
the tolerability of the combined metabolic cofactors including
L-serine, NAC, NR, and L-carnitine tartrate (salt form of L-carnitine)
at intended clinical doses and at levels 10- and 30-fold dose levels.
All critical operations and methods were performed according to
current standard operating procedures (SOPs) unless otherwise
noted. The experiments were approved by the SWETOX, Swedish
Toxicology Sciences Research Center Ethical Committee on Animal
Experiments. The Study Director reviewed the analytical data for
significant changes in any of the parameters.
The study comprised a 7-day repeated-dose phase with once-
daily doses of the combined metabolic cofactors at three dif-
ferent dose levels to investigate the clinical tolerability by
recordings of clinical signs and analysis of clinical pathology
parameters. Blood samples were taken for plasma exposure anal-
ysis at expected Tmax. Livers and kidneys were isolated and fix-
ated at necropsy for histopathological analyses and analysis of
organ exposure.
The oral route is the intended clinical administration route.
Details of numbers of animals and dose levels are included in
Appendix Table S1. Nine female rats were dosed once daily for
7 days. Animals were administered combined metabolic cofactors
formulated in tap water per orally (gavage) once daily for seven
consecutive days (Day 1–7). Three groups of three female rats/
group (Groups 1, 2, and 3) were dosed with the test formulation at
the dose levels described in Appendix Table S1. In Group 3, the dose
administered was not well tolerated at Days 1 and 2, and on Day 3,
the dose volume was reduced from 10 to 6.7 ml/kg/day, resulting
in a reduction of the high dose with on third for Days 3–7. The
animals were dosed in the morning (before noon). Animals were
allowed to recover for at least 20 h before any subsequent doses will
be administered (Appendix Table S2).
All animals were killed for scheduled necropsy on Day 8 by
exsanguinations under isoflurane and oxygen anesthesia. For sched-
uled necropsy, the thoracic and abdominal cavities and contents
were examined. Macroscopic abnormalities were recorded. Tissues
listed below were collected and fixed for further potential analysis
of tissue changes and tissue exposures. Samples of the following
tissues (kidneys, liver, intestine—jejunum, intestine—ileum, intes-
tine—colon, intestine—cecum, intestine—rectum, stomach/duode-
num) were taken at necropsy for possible future microscopic
pathology. Tissues were fixed and preserved in 4% formaldehyde,
for possible future processing and histological analysis.
Blood and urine sample collection for hematology and plasma
chemistry analysis
Animals bled All animals
Blood collection site and
schedule
Blood for scheduled hematology and plasma
chemistry was taken during termination at
necropsy from the orbital plexus, carotid
artery or according to Swetox GLP-SOP-07.
Blood sample volume and
anticoagulant
Plasma chemistry: at least 0.25 ml at
necropsy ml (lithium heparin). Hematology:
at least 20 ll (EDTA).
Analyses of samples Blood was analyzed using Exigo
(Hematology) and Vetscan (Plasma
Chemistry) equipment by the Responsible
technician for Pathology according to user
manuals or local SOPs.
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(continued)
Animals bled All animals
Information to be provided
with the samples
The samples were transferred for analyses
with the following sample information.
Sample list stating actual sampling times.
All samples were labeled with study
number, sample number, and animal
number and day/time point.
Hematology sample
procedures and analyses
Blood was analyzed within 60 min of
sampling. On the morning of analysis, the
Exigo analyzer was checked against a
reference sample provided by the
manufacturer, and a control sample analysis
cycle was performed.
For each study sample, SIG-41, animal ID,
sample number were manually entered on
the analyzer.
The analyzer was set to automatic printout,
and each individual sample printout was
collected and saved in the study folder. The
data are presented in Appendix Table S3.
Plasma chemistry sample
procedures
Plasma chemistry was analyzed as whole
blood. The Vetscan analyzer was calibrated
with calibration samples with known
plasma levels of each parameter before start
of analysis of study samples.
For each study sample, SIG-41, animal ID,
sample number were manually entered on
the analyzer.
The analyzer was set to automatic printout
and each individual sample printout was
collected and saved in the study folder. The
data are presented in Appendix Table S4.
Human calibration study
We performed a 5-day calibration study by recruiting nine healthy
male subjects without any medication (age 26–36 years, BMI 19.4–
34.5 kg/m2). After 21 months, we asked the subjects involved in
the study to run a follow-up control study and five of the subjects
responded positively. We recruited another five healthy subjects
and run a 1-day control study with 10 male subjects without any
medication (age 26–36 years, BMI 19.8–35.8 kg/m2) following the
same study design in the metabolic cofactor supplementation study.
The inclusion criteria are that the patients should be healthy without
any medication, no smokers, and no obesity. The exclusion criteria
are that if the patient has known disease or obesity. Informed
consent was obtained from all subjects involved in this study, and
the experiments conformed to the principles set out in the WMA
Declaration of Helsinki and the Department of Health and Human
Services Belmont Report. The study was approved by the Ethics
Committee at the University of Gothenburg, and it has been submit-
ted to https://ClinicalTrials.gov with the identifier: NCT03838822.
Detection of plasma metabolite levels
Measurement of plasma levels of metabolites was performed using
LC-MS. Briefly, the liquid chromatography–tandem mass spectrome-
try (LC-MS/MS) platform was based on a Waters ACQUITY ultraper-
formance liquid chromatography (UPLC) system and a Thermo-
Finnigan LTQ mass spectrometer operated at nominal mass
resolution, which was equipped with an electrospray ionization (ESI)
source and a linear ion trap (LIT) mass analyzer. The sample extract
was dried and then reconstituted in acidic or basic LC-compatible
solvents, each of which contained 12 or more injection standards at
fixed concentrations. One aliquot was analyzed using acidic positive
ion-optimized conditions and the other was analyzed using basic
negative ion-optimized conditions in two independent injections
using separate dedicated columns (Waters UPLC BEH C18–
2.1 × 100 mm, 1.7 lm). Extracts reconstituted in acidic conditions
were gradient eluted using water and methanol containing 0.1%
formic acid, whereas the basic extracts, which were also eluted using
water/methanol, contained 6.5 mM ammonium bicarbonate. The MS
analysis alternated between MS and data-dependent MS/MS scans
using dynamic exclusion, and the scan range was from 80 to
1,000 m/z. To identify the significant differences of plasma metabo-
lites compared to baseline (time T0), one-way ANOVA was employed
for each time points. Furthermore, to study associations between
plasma levels of metabolites supplemented by the cocktail and untar-
geted metabolites, Spearman correlation was used.
Detection of plasma inflammation protein marker levels
Plasma inflammation proteins were analyzed using a multiplex
proximity extension assay (Olink Bioscience, Uppsala, Sweden).
The kit provides a microtiter plate for measuring 92 protein
biomarkers in each plasma sample. Each well contains 96 pairs of
DNA-labeled antibody probes. Samples were incubated in the pres-
ence of proximity antibody pairs tagged with DNA reporter mole-
cules. When the antibodies pair bounds to their corresponding
antigens, the corresponding DNA tails form an amplicon by proxim-
ity extension, which can be quantified by high-throughput real-time
PCR. Briefly, 1 ll of each sample was mixed with 3 ll probe solu-
tion containing a set of 92 protein target-specific antibodies conju-
gated with distinctive DNA oligonucleotides. The mixture was
incubated overnight at 4°C and then added with 96 ll extension
solution containing extension enzyme and PCR reagents. The gener-
ated fluorescent signal allows the quantification of the protein using
BioMarkTM HD System, Fluidigm Corporation. To minimize inter-
and intra-run variation, the data are normalized using both an inter-
nal control (extension control) and an interplate control and then
transformed using a pre-determined correction factor. The pre-
processed data were provided in the arbitrary unit Normalized
Protein eXpression (NPX) on a log2-scale, which were then linear-
ized by using the formula 2NPX. A high NPX presents high protein
concentration. Limit of detection (LOD) for each protein was defined
as three standard deviations above the background. In this study,
Olink Inflammation panel has been used.
Statistics used for metabolomics and proteomics data analysis
Both plasma metabolomics and protein inflammation markers
dataset were pre-processed and analyzed in the same manner. First,
all data points in both supplementation and control studies were
normalized into fold changes by comparing to their baseline value
which is time 0. After the pre-processing, data were then respec-
tively compared at each time point with their baseline data using
one-way ANOVA in order to determine which metabolites/proteins
were showing statistically significant difference changes over time
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(FDR < 5%). In addition, data were also respectively compared at
each time point between supplementation and control studies using
one-way ANOVA to determine which metabolites/proteins were
showing statistical alteration in response to the metabolic cofactor
supplementation. Correlation analysis (Spearman) was also
performed between each metabolite with the supplemented metabo-
lites (serine, L-carnitine, and N-acetylcysteine for both conditions
and nicotinamide in the cocktail). In all analyses, missing values
were removed in a pairwise manner. ANOVA and correlation analy-
ses were performed using SciPy package in Python.
Genome-scale metabolic modeling (GEM) of liver
tissue metabolism
First, we generate a GEM for the reference state of liver in this
study. The liver GEM from our previous study is used as a starting
point and 62 additional exchange reactions were added. An ATP
hydrolysis reaction is also added to account for the resting energy
expenditure, and a low bound of 1,212.4 is added to it which is
calculated from previous experimental measurements (15 kcal/
liver/h). The constraints for internal reactions are set to +/ infinity
if they are reversible, or 0 to infinity if they are irreversible. The
upper and lower bounds for the exchange reactions of cocktail
substances are respectively set to 0.1 and 1 to force the uptake. The
exchange of nicotinamide and cysteine is also set to be uptake only
since they are closely related to the cocktail supplementation.
Constraints for exchange reactions are set based on previous studies
wherever possible. For the ones that has not reported, the
constraints are set based on metabolomics data. Specifically, uptake
and secretion for all metabolites are set to 1 except for irreversible
reactions whose lower bounds have to be 0, and some special
constraints are set to several reactions such as O2 uptake, H2O
exchange, etc., where the uptake should be unlimited. The objective
function for simulation is set as the total fatty acid oxidation flux in
mitochondria to reduce the solution space. This only counts the
fatty acid oxidation reactions in mitochondria, and each of them is
weighted by the total number of FADH2 and NADH produced. In
addition, the turnover flux of NAD+ and L-carnitine was calculated
by summing up the total absolute flux of them in all compartments.
An adapted RMetD was used to simulate the personalized meta-
bolic flux distribution with cocktail supplementation. First, we
sampled 1,000 times for the reference state model and used the
average flux as representative for the reference metabolic activity in
liver. Then, the fold changes for each metabolite are used to change
the upper/lower bounds of the corresponding exchange reaction.
For instance, if a metabolite is uptake by the model and its plasma
level is decreased with a fold change of two with cocktail supple-
mentation, it indicates that uptake of this metabolite is increased. In
this case, the lower bound of it will be set as its reference flux, and
its upper bound is set as two times of its reference flux. On the
contrary, if a metabolite is secreted by the model and its plasma
level is decreased with a fold change of 2, the upper bound of it will
be set as its reference flux, and its lower bound is set as its reference
flux divide by 2. After the change of constraints according to the
individualized changes, we again calculated the flux distribution of
each personalized GEM with 1,000 times random sampling and
obtained the personalized flux distribution with cocktail supplemen-
tation by averaging the sampled fluxes.
Prediction of clinical doses using an ordinary differential
equation model
The following model was used for simulation of the substances
serine, L-carnitine, and N-acetyl-cysteine:
dA
dt
¼ k1  A
dB
dt
¼ k1  A k1  B
dC
dt
¼ k1  B k2  C  C0ð Þ
where A represents the stomach, B represents the small intes-
tine, and C represents the blood. The constant C0 represents
the baseline concentration of the compound of interest. The
parameter k1 was used both as the rate constant for the stomach
and the small intestine since it reduced the degrees of
freedom for the model but provided a time delay which better
fitted the experimental data. Alternatively, one compartment
representing both the stomach and the small intestine could
have been used; however, this produced worse fit to the experi-
mental data.
Parameter values and standard errors for serine model
Parameter value RSE (%)
k1 0.60916 21.3
k2 18.16688 21.3
Parameter values and standard errors for L-carnitine model
Parameter value RSE (%)
k1 0.20350 168.8
k2 1.67995 164.2
Parameter values and standard errors for NAC model




The datasets and computer code produced in this study are provided
as Computer Code EV1.
Expanded View for this article is available online.
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